Adam Renslo, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Adam Renslo, PhD

Associate Professor of Pharmaceutical Chemistry, UCSF

Adam.Renslo@ucsf.edu

Box 2552, UCSF
San Francisco, CA 94143

UCSF Profiles

Cancer Center Membership

Program Member » Developmental Therapeutics

Research Summary

My research group is engaged at the interface of chemistry and biology. As medicinal chemists, we design and synthesize small molecules that modulate disease pathology at the level of the enzyme, cell, and whole animal, with current projects in cancer, infectious disease, and neurodegeneration. As chemical biologists, we employ novel small molecule probes to better understand biological pathways and the mechanisms of small molecule therapeutics. Using such small molecule probes, we are exploring the mechanisms underlying the action of artemisinin and related antimalarial drugs. Finally, we are inventing and employing new platform technologies in an effort to expand the realm of druggable target space and drug-like chemical space. These technologies include fragment-based approaches to target protein-protein interfaces and allosteric modulation of enzymes, the use of novel unnatural amino acids to discover cell-permeable peptides, and new targeted prodrug approaches in cancer and infectious disease.

Education

St. Olaf College, Northfield, MN, B.A., 05/1993, Chemistry
Massachusetts Institute of Technology, Ph.D., 05/1998, Organic Chemistry
The Scripps Research Institute, La Jolla, CA, Postdoctoral, 12/2000, Molecular Recognition


Professional Experience

  • 2000-2003
    Sr. Scientist, Group Leader, Medicinal Chemistry, Vicuron Pharmaceuticals
  • 2004-2005
    Associate Director, Medicinal Chemistry, Vicuron Pharmaceuticals (later Pfizer)
  • 2006-2011
    Assistant Adjunct Professor, Department of Pharmaceutical Chemistry, UCSF
  • 2011-2013
    Associate Adjunct Professor, Department of Pharmaceutical Chemistry, UCSF
  • 2006-present
    Associate Director, Small Molecule Discovery Center, UCSF
  • 2014-present
    Associate Professor, Department of Pharmaceutical Chemistry, UCSF

Selected Publications

  1. Spangler B, Fontaine SD, Shi Y, Sambucetti L, Mattis AN, Hann B, Wells JA, Renslo AR. A Novel Tumor-Activated Prodrug Strategy Targeting Ferrous Iron Is Effective in Multiple Preclinical Cancer Models. J Med Chem. 2016 Dec 22; 59(24):11161-11170.
    View on PubMed
  2. Gallagher CM, Garri C, Cain EL, Ang KK, Wilson CG, Chen S, Hearn BR, Jaishankar P, Aranda-Diaz A, Arkin MR, Renslo AR, Walter P. Ceapins are a new class of unfolded protein response inhibitors, selectively targeting the ATF6a branch. Elife. 2016; 5.
    View on PubMed
  3. Hallenbeck KK, Turner DM, Renslo AR, Arkin MR. Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery. Curr Top Med Chem. 2016 Jul 19.
    View on PubMed
  4. Spangler B, Morgan CW, Fontaine SD, Vander Wal MN, Chang CJ, Wells JA, Renslo AR. A reactivity-based probe of the intracellular labile ferrous iron pool. Nat Chem Biol. 2016 Sep; 12(9):680-5.
    View on PubMed
  5. Hearn BR, Jaishankar P, Sidrauski C, Tsai JC, Vedantham P, Fontaine SD, Walter P, Renslo AR. Structure-Activity Studies of Bis-O-Arylglycolamides: Inhibitors of the Integrated Stress Response. ChemMedChem. 2016 Apr 19; 11(8):870-80.
    View on PubMed
  6. Lauterwasser EM, Fontaine SD, Li H, Gut J, Katneni K, Charman SA, Rosenthal PJ, Bogyo M, Renslo AR. Trioxolane-Mediated Delivery of Mefloquine Limits Brain Exposure in a Mouse Model of Malaria. ACS Med Chem Lett. 2015 Nov 12; 6(11):1145-9.
    View on PubMed
  7. Mott BT, Eastman RT, Guha R, Sherlach KS, Siriwardana A, Shinn P, McKnight C, Michael S, Lacerda-Queiroz N, Patel PR, Khine P, Sun H, Kasbekar M, Aghdam N, Fontaine SD, Liu D, Mierzwa T, Mathews-Griner LA, Ferrer M, Renslo AR, Inglese J, Yuan J, Roepe PD, Su XZ, Thomas CJ. High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations. Sci Rep. 2015; 5:13891.
    View on PubMed
  8. Peniche AG, Renslo AR, Melby PC, Travi BL. Antileishmanial Activity of Disulfiram and Thiuram Disulfide Analogs in an Ex Vivo Model System Is Selectively Enhanced by the Addition of Divalent Metal Ions. Antimicrob Agents Chemother. 2015 Oct; 59(10):6463-70.
    View on PubMed
  9. Giles K, Berry DB, Condello C, Hawley RC, Gallardo-Godoy A, Bryant C, Oehler A, Elepano M, Bhardwaj S, Patel S, Silber BM, Guan S, DeArmond SJ, Renslo AR, Prusiner SB. Different 2-Aminothiazole Therapeutics Produce Distinct Patterns of Scrapie Prion Neuropathology in Mouse Brains. J Pharmacol Exp Ther. 2015 Oct; 355(1):2-12.
    View on PubMed
  10. Neitz RJ, Bryant C, Chen S, Gut J, Hugo Caselli E, Ponce S, Chowdhury S, Xu H, Arkin MR, Ellman JA, Renslo AR. Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas' disease. Bioorg Med Chem Lett. 2015 Nov 1; 25(21):4834-7.
    View on PubMed
  11. Nichols DA, Hargis JC, Sanishvili R, Jaishankar P, Defrees K, Smith EW, Wang KK, Prati F, Renslo AR, Woodcock HL, Chen Y. Ligand-Induced Proton Transfer and Low-Barrier Hydrogen Bond Revealed by X-ray Crystallography. J Am Chem Soc. 2015 Jul 1; 137(25):8086-95.
    View on PubMed
  12. Sidrauski C, Tsai JC, Kampmann M, Hearn BR, Vedantham P, Jaishankar P, Sokabe M, Mendez AS, Newton BW, Tang EL, Verschueren E, Johnson JR, Krogan NJ, Fraser CS, Weissman JS, Renslo AR, Walter P. Pharmacological dimerization and activation of the exchange factor eIF2B antagonizes the integrated stress response. Elife. 2015; 4:e07314.
    View on PubMed
  13. Chimenti MS, Bulfer SL, Neitz RJ, Renslo AR, Jacobson MP, James TL, Arkin MR, Kelly MJ. A Fragment-Based Ligand Screen Against Part of a Large Protein Machine: The ND1 Domains of the AAA+ ATPase p97/VCP. J Biomol Screen. 2015 Jul; 20(6):788-800.
    View on PubMed
  14. Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R, Nunneley JW, Barnard D, Pöhlmann S, McKerrow JH, Renslo AR, Simmons G. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res. 2015 Apr; 116:76-84.
    View on PubMed
  15. Turner DM, Tom CT, Renslo AR. Simple plate-based, parallel synthesis of disulfide fragments using the CuAAC click reaction. ACS Comb Sci. 2014 Dec 8; 16(12):661-4.
    View on PubMed
  16. Fontaine SD, DiPasquale AG, Renslo AR. Efficient and stereocontrolled synthesis of 1,2,4-trioxolanes useful for ferrous iron-dependent drug delivery. Org Lett. 2014 Nov 7; 16(21):5776-9.
    View on PubMed
  17. Fontaine SD, Spangler B, Gut J, Lauterwasser EM, Rosenthal PJ, Renslo AR. Drug delivery to the malaria parasite using an arterolane-like scaffold. ChemMedChem. 2015 Jan; 10(1):47-51.
    View on PubMed
  18. Neitz RJ, Chen S, Supek F, Yeh V, Kellar D, Gut J, Bryant C, Gallardo-Godoy A, Molteni V, Roach SL, Khare S, Stinson M, Chatterjee AK, Robertson S, Renslo AR, Arkin M, Glynne R, McKerrow J, Siqueira-Neto JL. Lead identification to clinical candidate selection: drugs for Chagas disease. J Biomol Screen. 2015 Jan; 20(1):101-11.
    View on PubMed
  19. Gable JE, Lee GM, Jaishankar P, Hearn BR, Waddling CA, Renslo AR, Craik CS. Broad-spectrum allosteric inhibition of herpesvirus proteases. Biochemistry. 2014 Jul 22; 53(28):4648-60.
    View on PubMed
  20. Debnath A, Shahinas D, Bryant C, Hirata K, Miyamoto Y, Hwang G, Gut J, Renslo AR, Pillai DR, Eckmann L, Reed SL, McKerrow JH. Hsp90 inhibitors as new leads to target parasitic diarrheal diseases. Antimicrob Agents Chemother. 2014 Jul; 58(7):4138-44.
    View on PubMed

Go to UCSF Profiles, powered by CTSI